This was the stock's second consecutive day of losses.

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...

The stock's fall snapped a two-day winning streak.

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $231 from $260 and keeps an Outperform rating on the shares as part of a ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.

Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...